Highlights IntelGenx Technologies Corp. Toronto S.E.

Equities

IGX

US45822R1014

End-of-day quote Toronto S.E. Other stock markets 06:00:00 2021-10-17 pm EDT			5-day change	1st Jan Change
0.78 ^CAD	+9.86%		+50.00%	+173.68%

Apr. 08	Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	CI
Apr. 05	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	Apr. 08	CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	Apr. 05	MT
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA	Apr. 05	CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises	Mar. 21	MT
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million	Feb. 20	MT
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx?s VetaFilm® Platform in Healthy Dogs and Cats	Feb. 05	CI
IntelGenx, Covenant Animal Health Partners Unit Sign Development, License Pacts for VetaFilm	Dec. 18	MT
IntelGenx Corp. Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	Dec. 18	CI
IntelGenx Brief: Announcing New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm	Dec. 18	MT
IntelGenx Announcing Shareholder Approval of Financing Transactions	Nov. 28	MT
IntelGenx Receives OK to Conduct Montelukast VersaFilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	Nov. 14	MT
IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease	Nov. 14	CI
IntelGenx Technologies Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
IntelGenx Announced Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray	Nov. 06	MT
IntelGenx Brief: Announciing Co-development and Commercialization of Cannabinoid-Infused VersaFilm Products with Tilray	Nov. 06	MT
Intelgenx Technologies Corp. Announces Co-Development and Commercialization of Cannabinoid-Infused Versafilm® Products with Tilray	Nov. 06	CI
Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States	23-09-26	CI
IntelGenx Provides Rizafilm U.S. Commercialization Update; Receives First Purchase Order From Gensco Pharma	23-09-21	MT
IntelGenx Brief: Provides RIZAFILM U.S. Commercialization Update; Receives first purchase order from Gensco Pharma	23-09-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IntelGenx Technologies Corp. Toronto S.E.

Equities

IGX

US45822R1014

Highlights

Filters